Baird Reiterates Outperform Rating on Longboard Pharmaceuticals Inc (LBPH)

Baird analyst Joel Beatty reiterated an Outperform rating and $60.00 price target on Longboard Pharmaceuticals Inc (NASDAQ: LBPH).

The analyst commented: "Nine-month OLE data in line with previous data, in our view. Longboard disclosed updated nine-month OLE data on bexicaserin today in conjunction with the ongoing
European Epilepsy Congress meeting. In our view, the nine-month OLE data look in line with six-month OLE data disclosed in June and the known mechanism of action."

For an analyst ratings summary and ratings history on Longboard Pharmaceuticals Inc click here. For more ratings news on Longboard Pharmaceuticals Inc click here.

Shares of Longboard Pharmaceuticals Inc closed at $34.86 yesterday.

You May Also Be Interested In

• Correction: Kepler Cheuvreux Upgrades Siemens AG (SIE:GR) (SIEGY) to Hold
• Morgan Stanley Resumes OMV AG (OMV:AV) (OMVKY) at Equalweight
• Deutsche Bank Resumes Kloeckner & Co SE (KCO:GR) at Hold